Results 21 to 30 of about 12,625 (176)

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.

PLoS ONE
Nirmatrelvir/Ritonavir, acting as an effective agent against COVID-19, has achieved considerable results in clinical studies in terms of drug efficacy. However, there is little research about its medication safety.
Ji Sun, Xuanyu Deng, Juanjuan Huang, Gefei He, Shiqiong Huang   +4 more
doaj   +2 more sources

Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection

Journal of Global Antimicrobial Resistance
Background: Nirmatrelvir-ritonavir is effective in the treatment of SARS-CoV-2 infection. It can cause drug‒drug interactions (DDIs), even several days after withdrawal, due to irreversible inhibition of the cytochrome enzyme.
Yun Han, Yonglan Gou, Jieqiong Liu, Lingyan Yu, Yuhua Zhao, Zhenwei Yu   +5 more
doaj   +2 more sources

Risk of acute liver injury following the nirmatrelvir/ritonavir use [PDF]

, 2023
Background: Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported as adverse events of nirmatrelvir/ritonavir users in the EPIC-HR trial.
LY Mak (16544529), MF Yuen (16545504), CH So (16717425), BJ Cowling (15834218), CKH Wong (16544469), KTK Lau (16544472), WY Cheng (16544523), EHY Lau (16543686), GM Leung (15834224), ICH Au (16544475)   +9 more
core   +2 more sources

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

BMC Infectious Diseases
Background The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood.
Ee Vien Low, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +10 more
doaj   +2 more sources

NIRMATRELVIR/RITONAVIR (NIRI) EM PACIENTES COM COVID-19 E MALIGNIDADES HEMATOLÓGICAS: RELATO DO EPICOVIDEHA (REGISTRO INTERNACIONAL ONLINE DE PACIENTES COM MALIGNIDADES HEMATOLÓGICAS, INFECTADOS POR SARS-COV-2)

Brazilian Journal of Infectious Diseases, 2023
Introdução: O tratamento com NIRI diminui a taxa de hospitalização em pacientes imunocompetentes com COVID-19, mas os dados sobre a eficácia em pacientes com malignidade hematológica (MH) são escassos.
Jon Salmanton-García, Francesco Marchesi, Livio Pagano, Oliver A. Cornely   +3 more
doaj   +1 more source

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.
Jiayi Yan, Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou, Shan Mou   +11 more
doaj   +1 more source

Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation [PDF]

, 2023
To date, there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant persons. This target trial emulation study aimed to address this
BJ Cowling (15834218), CKH Wong (16544469), KTK Lau (16544472), Y Daoud (17661372), EHY Lau (16543686), MSH Chung (16544478), KW Cheung (17661369), GM Leung (15834224), ICH Au (16544475)   +8 more
core   +2 more sources

Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study

International Journal of Infectious Diseases, 2023
Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death ...
Ee Vien Low, Mohan Dass Pathmanathan, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +12 more
doaj   +1 more source

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice

, 2023
Nirmatrelvir/ritonavir (Paxlovid) is indicated in patients who are at high risk of progressing to severe COVID-19. Many of these patients are concomitantly prescribed various medications for other indications. Ritonavir has no activity against SARS-CoV-2,
Magdalena Niedzielko, Dagmara Mirowska-Guzel, Rafał Kułakowski   +2 more
core   +1 more source

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context

EClinicalMedicine, 2023
Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Zoey Cho Ting Wong, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Xue Li, Carlos King Ho Wong, Ivan Fan Ngai Hung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan   +10 more
doaj   +1 more source